Register Form

Please fill up the form below:

ECE 2017

This Event already finished.

European Congress of Endocrinology

  • 20 May 2017 to 23 May 2017
  • Lisboa Congress Centre
  • Portugal

Whats About

The endocrine glands of the human body play a vital role in maintaining a balance in the level of the hormones within the human body. Over the years, the study of the endocrine glands of humans i.e Endocrinology has undergone an unprecedented development in term of diagnosis, treatment and rehabilitation. The ECE provides to people involved in the field of endocrine sciences a place to air, share contemplate and thereafter act upon the various developments and roadblocks in the field of endocrinology. The European Congress of Endocrinology, ECE 2017 is taking place in Lisbon, Portugal from 20-23 May. Doctors, surgeons and endocrinologists from around the world gather at this conference to discuss and share the latest scientific and clinical research work for better diagnosis, treatment and after care in the field of endocrinology. All aspects of endocrine science and medication related topics are discussed and presented by professionals in the form of poster session, symposia, plenary sessions, etc. Be a part of this congress for further developing the field of endocrinology by increasing your and others knowledge about endocrine science and how the latest technology can help in shaping a good future for fast diagnosis, treatment and recovery in the medical field of endocrinology. Dates to remember:

  1. Early bird deadline – 31st March 2017
  2. Abstract author notification – March 2017


Registration Details
 

Early Bird Registration

Available until 23:59 GMT on 31 March 2017

 

Standard Registration

1 April 2017 – 23:59 GMT on 18 May 2017

 

Onsite Registration

19 May 2017 – 23 May 2017

 

ESE MEMBER

 

€450

€550

€600

NON-MEMBER

 

€750

€850

€900

FELLOW/STUDENT ESE MEMBER

 

€225

€275

€325

FELLOW/STUDENT NON-MEMBER

 

€500

€600

€650

NURSE REGISTRATION

 

€100

€150

€200

Program Highlights of the Events

  • Day 1 (20 May)
  • Day 2 (21 May)
  • Day 3 (22 May)
  • Day 4 (23 May)

    • 12:00-19:45 – Registration
    • 12:00 – Pre-Congress courses and meetings
    • 17:30-18:15 – ECE 2017 opening ceremony
    • 18:15-18:45 – Geoffery Harris Lecture
    • Towards hormone based precision medicines for metabolic diseases
    • 18:45-19:15 – EJE prize lecture
    • Hypothalamic AMPK : A global target against obesity:
    • 19:15-19:45 – Plenary 1: The fantastical world of hormones
    • 19:45-21:00 – Welcome reception

      • 08:00-17:00 – Registration
      • 08:15-09:00 – Meet the expert 1
      • MTE 1 : How to manage diabetes in the elderly
      • 08:15-09:00 – Meet the expert 2: Diagnosis and treatment of GH-deficiency : From transition to senescense
      • 08:15-09:00 – Meet the expert 3 : Hormone secreting adrenal tumors in pregnancy
      • 08:15-09:00 – Meet the expert 4 : Optimized treatment for congenital hypothyroidism throughout lifetime
      • 08:15-09:00 – Meet the expert 5 : Modern spectrum of bone turnover markets: Are they clinically useful
      • 08:15-09:00 – Meet the nurse expert: endocrine late effects of cancer treatment in children: providing nursing care and seamless transition
      • 08:15-09:00 – Meet the basic scientist : unraveling the role of transient receptor potential channels in endocrine regulation and metabolism
      • 09:15-09:30 – Presidential address
      • 09:30-10:00 – Plenary 2: The secret life of FGF21
      • 10:00-10:30 –Tea and coffee
      • 10:30-12:00 – Symposium 1 : Clinical updates in hypoparathyrodism
      • 10:30 – S1.1: Congenital hypoparathyroidism
      • 11:00 – S1.2: Acquired hypoparathyroidism
      • 11:30 – S1.3: therapeutic approaches
      • 10:30-12:00 – Symposium 2 : Evolving diagnostics in adrenal and neuroendocrine tumors
      • 10:30 – S2.1: Role of genetic and biomarker tests for diagnosis of neuroendocrine tumours
      • 11:00 – S2.2: Current status in morphological imaging in adrenal and gastrointestinal tumors
      • 11:30 – S2.3: current status in functional imaging
      • 10:30-12:00 – Symposium 3: From the pituitary to the periphery
      • 10:30 – S3.1: Implication of the prolctin receptor in humans
      • 11:00 – S3.2: GHR: Are there benefits of endocrine defects?
      • 11:30 – S3.3: Somatostain receptors: News in the pituitary, lessons for the periphery
      • 10:30-12:00 – Symposium 4: Obesity joint session
      • 10:30-12:00 – Symposium 5: Eye session – Turn your face to the sunshine
      • 10:30-12:00 – Guidelines session 1: management of Turner syndrome
      • 10:30-12:00 – Nurses session
      • 12:15-13:00 – Debate 1: Is there a role for medical therapy for non-functioning pituitary adenomas? For and Against
      • 12:15-13:45 – Nurses session
      • 13:15-14:15 – Lunch and poster viewing
      • 14:15-15:00 – New scientific approach 1
      • 14:15 – NSA 1 : Identifying molecular signatures for cancer patient stratification via metabolisms and integrative bioinformatics
      • 14:5-15:00 – New scientific approach 2
      • 14:15 – NSA 2 : Exosome profiling: Potential in cancer diagnosis and stratification
      • 15:30-16:15 – Debate 2: Incidentally discovered non-functioning pancreatic NENs: Surgery or not? For and against
      • 15:30-17:00 – Symposium 6 : Treatment of hypothyroidism:What have we learned?
      • 15:30 – S6.1: What is the clinical relevance of deiodinase polymorphisms?
      • 16:00 – S6.2: T4/T3 combination therapy: is there a true effect?
      • 16:30 – S6.3: Rebuilding your own thyroid from stem cells; the future therapy of hypothyroidism?
      • 15:30-17:00 – Symposium 7: Crosstalk between bone and the other organ(ism)s
      • 15:30 – S7.1: Immune system
      • 16:00 – S7.2: Regulation of adaptation to exercise
      • 16:30 – S7.3: Microbiome
      • 15:30-17:00 – Symposium 8: Predictors of therapeutic response in functioning pituitary tumors
      • 15:30 – S8.1: Molecular profiling
      • 16:00 – S8.2: Imaging
      • 16:30 – S8.3: Clinical application and practice
      • 15:30-17:00 – Symposium 9: Novel type 2 diabetes treatment: Beyond glycaemic control
      • 15:30 – S9.1: Experimental models
      • 16:00 – S9.2: Clinical studies on GLP1: Cardiovascular outcomes
      • 16:30 – S9.3: SGLT2 long term protective effects
      • 15:30-17:00 – Symposium 10: The challenges of male fertility
      • 15:30 – S10.1: Manipulating testicular androgen production to promote lifelong male health
      • 16:00 – S10.2: Fertility preservation in pre-pubertal and young males
      • 16:30 – S10.3: Pubertal induction and hormone replacement in young males
      • 17:00-17:30 – Tea and coffee
      • 17:30-18:00 – Plenary 3
      • 17:30 – PL3 : Update on regulation of steroidogenesis by aberrant hormone receptors

        • 08:00-17:00 – Registration
        • 08:15-09:00 – Meet the expert 6: How to best to utilize technology in diabetes?
        • 08:15-09:00 – Meet the expert 7: When and which treatment to use in Graves disease?
        • 08:15-09:00 – Meet the expert 8: How best to manage neuroendocrine tumors? Towards a new algorithm
        • 08:15-09:00 Meet the expert 9: Sarcopenia: Why should we care?
        • 08:15-09:00 – Meet the basic scientist 2: Neuroimaging in obesity and diabetes: Regulation and dysregulation of appetite and satiety
        • 08:15-09:00 – Meet the nurse expert: Providing nursing care for the adult patient with endocrine late effects of cancer treatment
        • 08:15-09:00 – Meet the expert 10: Contraception in women with obesity, metabolic syndrome and diabetes
        • 09:00-09:30 – Plenary 4: PL4: the role of brain insulin resistance for the development of prediabetic phenotypes
        • 09:30-10:00- European Hormone Medal Lecture
        • 10:00-10:30 – Tea and coffee
        • 10:30-12:00 – Symposium 11: new roles for nuclear receptors
        • 10:30 – S11.1: LXR in male fertility
        • 11:00 – S11.2: Crosstalk between estrogen signaling and DNA damage repair
        • 11:30 – S11.3: The role of androgens in bone
        • 10:30-12:00 – Symposium 12: New developments in Graves orbitopathy
        • 10:30 – S12.1: the orbital fibroblast: A key player and target for therapy in graves orbitopathy
        • 11:00 – S12.2: Management of Graves orbitopathy
        • 11:30 – S12.3: How to predict relapse in Graves orbitopathy
        • 10:30-12:00 – Symposium 13: Challenging pituitary diseases
        • 10:30 – S13.1: Hypophysitis
        • 11:00 – S13.2: Empty sella
        • 11:30 – S13.3: Sellar masses
        • 10:30-12:00 – Symposium 14: Searching for the cause and approach in ectopic hormone syndromes
        • 10:30 – S14.1: rare Cushing’s
        • 11:00 – S14.2: Rare acromegaly
        • 11:30 – S14.3: Rare hyperglycemia
        • 10:30-12:00- Symposium15: metabolic surgery- Mechanisms to clinical results
        • 10:30 – S15.1: The upper gut-incretin theory
        • 11:00 – S15.2: the role of bile in metabolic surgery
        • 11:30 – S15.3: long term effects of metabolic surgery
        • 12:15-13:00 – Debate 3: Drug holiday in osteoporosis. For and against
        • 12:15-13:15 – Guideline session 2: aggressive pituitary tumors
        • 13:15-14:15 – Lunch and poster viewing
        • 14:15-15:00 – New scientific approach 3 : Genomic approaches on epigenetics
        • 14:00-15:00 –New scientific session 4: What is the CRISPR CAS9 technology
        • 15:30-16:15 – Debate 4: Is cardiovascular risk increased in women with PCOS? For and against
        • 15:30-17:00 – Symposium 16: Late-breaking the PCSK9 revolution
        • 15:30 – S16.1: Beyond LDL lowering: The pleiotropic roles of PCSK9
        • 16:00 – S16.2: new strategies for inhibiting PCSK9
        • 16:30 – S16.3: PCSK9 inhibition in clinical practice: Present and future
        • 15:30-17:00 – Symposium 17: What endocrinologists should know about the genomics of endocrine tumors
        • 15:30 – S17.1: Clinical consequences of the recent genomics findings in thyroid cancer
        • 16:00 – S17.2: Clinical implications of SDH mutations
        • 16:30 – S17.3: will genomics help to finally classify NETs?
        • 15:30-17:00 – Symposium 18: hyperandrogenism: Challenges in clinical management
        • 15:30 – S18.1: Hyperandrogenic states- Pitfalls in diagnostic approach
        • 16:00 – S18.2: metabolic perspectives for the non0classical CAH
        • 16:30 – S18.3: Hyperandrogenism and cardiometabolic risk
        • 15:30-7:00 – Symposium 19: How to incorporate the new guidelines for thyroid cancer in my clinical practice
        • 15:30 – S19.1: treatment and follow up of microcarcinomas
        • 16:00 – S19.2: When and how should we perform extensive surgery?
        • 16:30 – S19.3: Dynamic risk stratification in low risk v/s high risk patients
        • 15:30-17:00 – Symposium 20: Beta cell replacement and plasticity
        • 15:30 – S20.1: stem cell approach
        • 16:00 – S20.2: New strategies for beta cell replacement
        • 16:30 – S20.3: Beta cell replacement and plasticity
        • 15:30-16:30 – Guidelines sessions 2: aggressive pituitary tumors
        • 15:30-17:00 – Nurses sessions
        • 17:00-17:30 – Tea and coffee
        • 17:30-18:00 – clinical endocrinology trust lecture
        • 18:00-18:30 – Plenary 5: Browning of adipose tissue and metabolic regulation

          • 08:00-17:00 – Registration
          • 08:15-09:00 – Meet the expert 11: Drug induced osteoporosis
          • 08:15-09:00 – Meet the expert 12: A modern approach for treatment PCOS
          • 08:15-09:00 – Meet the expert 13: What can new insulins provide for management of diabetes?
          • 08:15-09:00 – Meet the expert 15: Gaucher’s disease- interdisciplinary management
          • 08:15-09:00 – Meet the expert 16: New treatment approaches in dyslipidemia
          • 08:15-09:00 – Meet the basic scientist: MicroRNAs and the regulation of glucose and lipid metabolism
          • 09:00-09:39 – IPSEN foundation lecture
          • 09:30-10:00 – Tea and coffee
          • 10:00-11:30 – symposium 21: Environmental influences on endocrine systems
          • 10:00 – S21.1: lifestyle and environmental factors in metabolic diseases
          • 10:30 – S21.2: evidence on reproductive disorders through endocrine disruption in utero
          • 11:00 – S21.3: Euthyroid- Towards a euthyroid Europe
          • 10:00-11:30 – Symposium 22: Rare bone diseases
          • 10:00 – S22.1: Approach for clinicians
          • 10:30 – S22.2: Osteogenesis imperfect and Ehlers-Danlos syndrome
          • 11:00 – S22.3: Fibrous dysplasia
          • 10:00-11:30 – Symposium 23: Endo Oncology: Prolactin, GH and metabolic hormones in oncology pathogenesis
          • 10:00 – S23.1: Prolactin regulation of prostate stem cells- Potential implications in prostate cancer
          • 10:30 – S23.2: Does GH enable neoplastic growth?
          • 11:00 – S23.3: Is reducing insulin resistance relevant to prevent cancer?
          • 10:00-11:30 – Symposium 24: Obesity: Pharmacological solutions
          • 10:00 – S24.1: MSH analogs
          • 10:30 – S24.2: The future drugs to come
          • 11:00 – S24.3: US experience update
          • 10:00-11:30 – Symposium 25: HPA axis regulation during a woman’s life- Impact on metabolic outcomes
          • 10:00 – S25.1: Molecular basis of the HPA axis regulation in woman during stress and pregnancy
          • 10:30 – S25.2: HPA axis, insulin resistance and adipocytokines in the fetal maternal unit
          • 11:00 – S25.3: 11B-hydroxysteroid dehydrogenase avtivity, androgen excess and metabolic outcomes in woman
          • 12:15-13:00 – Debate 5: Should we still ablate all patients undergoing total throidectomy for thyroid cancer? For and against
          • 12:45-13:45 – Lunch and poster viewing
          • 13:00-13:45 – ESE annual general meeting
          • 13:45-14:30 – New scientific approach 5: GPCRs- From crystallization to the development of new treatment strategies for endocrine diseases
          • 13:45 – NSA 5.1 : New strategies to crystallize endocrine disease related GPCRs
          • 14:05 – NSA 5.2 : Small molecule agonists and antagonists as potential new therapeutics targeting the TSH receptor
          • 13:45-14:30 – new scientific approach 6: Mitochondrial epigenetics
          • 15:00-16:30 – Symposium 26: Tissue specific defects in thyroid hormone action
          • 15:00 – S26.1 – Mouse models to study tissue specific hypothyroidism
          • 15:30 – S26.2: Syndromes of decreased sensitivity to TH
          • 16:00 –S26.3: restoring TH action in patients with transporter defects- The triac trial
          • 15:00-16:30 – Symposium 27: Vitamin D beyond bone
          • 15:00 – S27.1: Heart and vessels
          • 15:30 – S27.2: Fertility
          • 16:00 – S27.3: Muscles
          • 15:00-16:30 – Symposium 28: Sleep, love and reproduction
          • 15:00 – S28.1: sleep disturbances
          • 15:30 – : S28.2: Oxytocin
          • 16:00 – S28.3: Kisspeptin
          • 15:00-16:30 – Symposium 29: Novel predictors of diabetes
          • 15:00 –S29.1: Type 1 Diabetes
          • 15:30 – S29.2: Clinical and genetic indicators
          • 16:00 – S29.3: NAFLD, diabetes and CVD
          • 15:00-16:30 – Symposium 30: Moving away from old fashioned steroidogenesis – What are the clinical implications?
          • 15:00 – S30.1: Clinical relevance of alternative synthesis of androgens
          • 15:30 – S30.2: Clinical relevance of steroid precursors in adrenocortical tumors
          • 16:00 – S30.3: Glucocorticoid production in primary aldosteronism- From mechanisms to clinical implications
          • 15:30-16:15 – Debate 6: Is it time for initial combination in type 2 diabetes?
          •  For and against
          • 16:30-17:00 –Tea and coffee
          • 17:00-17:15 – ESE young investigator awards ceremony
          • 17:15-17:45 – Plenary 6 : thyroid oncology in the crossroads of  precision and narrative medicine
          • 17:45-18:15 – Closing Ceremony